These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 33270642)

  • 21. A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection.
    Kose N; Fox JM; Sapparapu G; Bombardi R; Tennekoon RN; de Silva AD; Elbashir SM; Theisen MA; Humphris-Narayanan E; Ciaramella G; Himansu S; Diamond MS; Crowe JE
    Sci Immunol; 2019 May; 4(35):. PubMed ID: 31101672
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effectiveness of antiviral agents with broad-spectrum activity against chikungunya virus varies between host cell lines.
    Franco EJ; Rodriquez JL; Pomeroy JJ; Hanrahan KC; Brown AN
    Antivir Chem Chemother; 2018; 26():2040206618807580. PubMed ID: 30354193
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel Mutations in nsP2 Abolish Chikungunya Virus-Induced Transcriptional Shutoff and Make the Virus Less Cytopathic without Affecting Its Replication Rates.
    Akhrymuk I; Lukash T; Frolov I; Frolova EI
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30487275
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chikungunya Virus Strains Show Lineage-Specific Variations in Virulence and Cross-Protective Ability in Murine and Nonhuman Primate Models.
    Langsjoen RM; Haller SL; Roy CJ; Vinet-Oliphant H; Bergren NA; Erasmus JH; Livengood JA; Powell TD; Weaver SC; Rossi SL
    mBio; 2018 Mar; 9(2):. PubMed ID: 29511072
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic administration of a recombinant human monoclonal antibody reduces the severity of chikungunya virus disease in rhesus macaques.
    Broeckel R; Fox JM; Haese N; Kreklywich CN; Sukulpovi-Petty S; Legasse A; Smith PP; Denton M; Corvey C; Krishnan S; Colgin LMA; Ducore RM; Lewis AD; Axthelm MK; Mandron M; Cortez P; Rothblatt J; Rao E; Focken I; Carter K; Sapparapau G; Crowe JE; Diamond MS; Streblow DN
    PLoS Negl Trop Dis; 2017 Jun; 11(6):e0005637. PubMed ID: 28628616
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mosquito saliva induced cutaneous events augment Chikungunya virus replication and disease progression.
    Agarwal A; Joshi G; Nagar DP; Sharma AK; Sukumaran D; Pant SC; Parida MM; Dash PK
    Infect Genet Evol; 2016 Jun; 40():126-135. PubMed ID: 26925703
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A small antigenic determinant of the Chikungunya virus E2 protein is sufficient to induce neutralizing antibodies which are partially protective in mice.
    Weber C; Büchner SM; Schnierle BS
    PLoS Negl Trop Dis; 2015 Apr; 9(4):e0003684. PubMed ID: 25905779
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alpha interferon as an adenovirus-vectored vaccine adjuvant and antiviral in Venezuelan equine encephalitis virus infection.
    O'Brien L; Perkins S; Williams A; Eastaugh L; Phelps A; Wu J; Phillpotts R
    J Gen Virol; 2009 Apr; 90(Pt 4):874-882. PubMed ID: 19264673
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression and Characterization of Yeast Derived Chikungunya Virus Like Particles (CHIK-VLPs) and Its Evaluation as a Potential Vaccine Candidate.
    Saraswat S; Athmaram TN; Parida M; Agarwal A; Saha A; Dash PK
    PLoS Negl Trop Dis; 2016 Jul; 10(7):e0004782. PubMed ID: 27399001
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Visualization of chikungunya virus infection
    Zhang HL; Dong HL; Zhang YN; Xu LL; Deng CL; Li XF; Li XD; Ye HQ; Yuan ZM; Qin CF; Zhang B
    Emerg Microbes Infect; 2019; 8(1):1574-1583. PubMed ID: 31682177
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of Immunogenicity and Neutralisation Efficacy of Viral-Vectored Vaccines Against Chikungunya Virus.
    López-Camacho C; Kim YC; Blight J; Lazaro Moreli M; Montoya-Diaz E; Huiskonen JT; Kümmerer BM; Reyes-Sandoval A
    Viruses; 2019 Apr; 11(4):. PubMed ID: 30987160
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic and prophylactic treatment with a virus-specific antibody is highly effective in rodent models of Chikungunya infection and disease.
    Julander JG; Anderson N; Haese N; Andoh T; Streblow DN; Cortez P; Carter K; Marniquet X; Watson H; Mandron M
    Antiviral Res; 2022 Jun; 202():105295. PubMed ID: 35339583
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential Transmission of Antiviral Drug-Resistant Chikungunya Viruses by
    Delang L; Yen PS; Vallet T; Vazeille M; Vignuzzi M; Failloux AB
    mSphere; 2018 Aug; 3(4):. PubMed ID: 30135220
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Monoclonal Antibodies as Prophylactic and Therapeutic Agents Against Chikungunya Virus.
    Clayton AM
    J Infect Dis; 2016 Dec; 214(suppl 5):S506-S509. PubMed ID: 27920182
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiviral Phosphorodiamidate Morpholino Oligomers are Protective against Chikungunya Virus Infection on Cell-based and Murine Models.
    Lam S; Chen H; Chen CK; Min N; Chu JJ
    Sci Rep; 2015 Jul; 5():12727. PubMed ID: 26224141
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chikungunya Virus Vaccine Candidates with Decreased Mutational Robustness Are Attenuated
    Carrau L; Rezelj VV; Noval MG; Levi LI; Megrian D; Blanc H; Weger-Lucarelli J; Moratorio G; Stapleford KA; Vignuzzi M
    J Virol; 2019 Sep; 93(18):. PubMed ID: 31270226
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Disruption of the Opal Stop Codon Attenuates Chikungunya Virus-Induced Arthritis and Pathology.
    Jones JE; Long KM; Whitmore AC; Sanders W; Thurlow LR; Brown JA; Morrison CR; Vincent H; Peck KM; Browning C; Moorman N; Lim JK; Heise MT
    mBio; 2017 Nov; 8(6):. PubMed ID: 29138302
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vector competence of populations of Aedes aegypti from three distinct cities in Kenya for chikungunya virus.
    Agha SB; Chepkorir E; Mulwa F; Tigoi C; Arum S; Guarido MM; Ambala P; Chelangat B; Lutomiah J; Tchouassi DP; Turell MJ; Sang R
    PLoS Negl Trop Dis; 2017 Aug; 11(8):e0005860. PubMed ID: 28820881
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Suramin treatment reduces chikungunya pathogenesis in mice.
    Kuo SC; Wang YM; Ho YJ; Chang TY; Lai ZZ; Tsui PY; Wu TY; Lin CC
    Antiviral Res; 2016 Oct; 134():89-96. PubMed ID: 27577529
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus.
    Brandler S; Ruffié C; Combredet C; Brault JB; Najburg V; Prevost MC; Habel A; Tauber E; Desprès P; Tangy F
    Vaccine; 2013 Aug; 31(36):3718-25. PubMed ID: 23742993
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.